← Leaderboards
Gloria Vittone Echeverria
Baylor College Of Medicine
$1,969,720
Attributed
$1,969,720
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $650.9K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,969,720 · 2
By mechanism
R37$1,496,680 · 1
K22$473,040 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Helen E Heslop$25,308,937
- Suzanne A Fuqua$14,426,929
- Brendan Hl Lee$62,781,623
- Harvey S Levin$16,764,266
- Maria E Suarez-Almazor$18,131,111
Others in their field
Other Emerging Leaders on “Triple-Negative Invasive Breast Carcinoma”
- Ozgur Sahin · Medical University Of South Carolina$6,265,859
- Brooke M Emerling · Sanford Burnham Prebys Medical Discovery Institute$4,446,740
- Jeremy Goecks · Johns Hopkins University$4,197,701
- Xi Chen · Baylor College Of Medicine$3,780,594
- Justin Adam Colacino · University Of Michigan At Ann Arbor$3,723,609
- Gaorav P. Gupta · Duke University$3,574,829
Research focus
Triple-Negative Invasive Breast CarcinomaMitochondriaBreast Cancer PatientMetabolicChemotherapyGeneticNeoplastic CellMalignant Breast NeoplasmOxidative PhosphorylationCessation Of LifeNeoadjuvant TherapyAutomobile DrivingCellsBiopsyRefractoryMetabolismIn VitroIn VivoEquilibriumInsightBreast Cancer CellChemoresistancePhenotypeRegulation
Grant awards (7)
Metabolic adaptation in residual triple negative breast cancer following chemotherapy$410,936
R37 · FY2025 · CA · contact PI
Metabolic adaptation in residual triple negative breast cancer following chemotherapy$240,000
R37 · FY2025 · CA · contact PI
Metabolic adaptation in residual triple negative breast cancer following chemotherapy$401,438
R37 · FY2024 · CA · contact PI
Metabolic adaptation in residual triple negative breast cancer following chemotherapy$444,306
R37 · FY2023 · CA · contact PI
Characterizing and targeting intra-tumor heterogeneity in triple negative breast cancer chemoresistance and multi-organ metastasis$157,680
K22 · FY2022 · CA · contact PI
Characterizing and targeting intra-tumor heterogeneity in triple negative breast cancer chemoresistance and multi-organ metastasis$157,680
K22 · FY2021 · CA · contact PI
Characterizing and targeting intra-tumor heterogeneity in triple negative breast cancer chemoresistance and multi-organ metastasis$157,680
K22 · FY2020 · CA · contact PI